君实生物(01877.HK)与杭州多禧签署药品开发及许可合同
君实生物(01877.HK)公布,与杭州多禧签署药品开发及许可协议。据此,公司获得许可使用DAC-002,在授权许可区域(除日本、韩国以外的全部亚洲国家及区域)内负责DAC-002後续的临床试验、药品注册、商业化生产、销售及其他商业活动。杭州多禧将获得3,000万人民币(下同)首付款和226.8万元的样品制备费用,公司并将按研发进展支付累计不超过2.7亿元的研发及上市里程碑款,以及在DAC-002实现商业化销售後支付年销售收入6%-10%的收益分成。
DAC-002是抗Trop2单抗通过智能连结体偶联抗微管蛋白Tubulysin B类似物的药物,主要用於治疗Trop2阳性三阴性乳腺癌、小细胞肺癌、胰腺癌等实体肿瘤。目前已向国家药品监督管理局申报临床试验并获受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.